Preliminary Assessment of a Neuropathic Pain Treatment and Referral Algorithm for Patients With Cancer

被引:23
作者
Smith, Ellen M. Lavoie [1 ]
Bakitas, Marie A. [2 ,3 ]
Homel, Peter [4 ]
Piehl, Mark [4 ]
Kingman, Linda [3 ]
Fadul, Camilo E. [2 ,3 ]
Bookbinder, Marilyn [4 ]
机构
[1] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA
[2] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[3] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA
[4] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA
关键词
Cancer; neuropathic pain; evidence-based treatment; algorithm; LIDOCAINE PATCH 5-PERCENT; DIABETIC PERIPHERAL NEUROPATHY; QUALITY-OF-LIFE; DOUBLE-BLIND; POSTHERPETIC NEURALGIA; CONTROLLED-TRIAL; VS; PLACEBO; EFFICACY; MORPHINE; ANTIDEPRESSANTS;
D O I
10.1016/j.jpainsymman.2011.03.017
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. The purpose of this case series study was to pilot test an evidence-based neuropathic pain (NP) treatment and referral algorithm for use by oncology nurses when managing cancer-related NP. Objectives. The primary study objective was to assess patient-reported outcomes (pain severity, changes in activities of daily living, and satisfaction) resulting from algorithm use. Methods. Outpatients (n = 20) with cancer-related NP scores >= 4 on a 0-10 numeric rating scale participated in the study. NP assessment, treatment, and referral to ancillary providers were guided by an evidence-based NP algorithm that was implemented by oncology nurse practitioners. Based on efficacy evidenced through randomized clinical trials published at the time of study implementation, the following drugs were included in the algorithm: lidocaine patch, gabapentin, oxycodone, tramadol, morphine, methadone, duloxetine, pregabalin, and nortriptyline. Recommendations for starting dose, dose escalation, drug combinations, treatment duration, and contraindications were included for first-tier drugs. Patient-reported outcomes (pain severity, functional capacity, and satisfaction) were assessed monthly over 12 weeks. Results. Average NP severity (P = 0.001), general activity (P < 0.001), mood (P = 0.002), walking ability (P = 0.01), ability to perform normal work (P = 0.002), relationships (P = 0.002), sleep (P = 0.01), life enjoyment (P < 0.001), and patient satisfaction (P = 0.003) all improved by 12 weeks. Conclusion. Evidence from this pilot study suggests that NP evidence-based treatment may result in improved symptoms, function, and patient satisfaction. A randomized controlled trial is needed to further assess algorithm efficacy. J Pain Symptom Manage 2011;42:822-838. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:822 / 838
页数:17
相关论文
共 64 条
  • [1] Neuropathic pain in the cancer patient
    Allen, RR
    [J]. NEUROLOGIC CLINICS, 1998, 16 (04) : 869 - +
  • [2] [Anonymous], Brief Pain Inventory
  • [3] Self efficacy as a mediator of the relationship between pain intensity, disability and depression in chronic pain patients
    Arnstein, P
    Caudill, M
    Mandle, CL
    Norris, A
    Beasley, R
    [J]. PAIN, 1999, 80 (03) : 483 - 491
  • [4] Background noise - The experience of chemotherapy-induced peripheral neuropathy
    Bakitas, Marie A.
    [J]. NURSING RESEARCH, 2007, 56 (05) : 323 - 331
  • [5] Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment
    Baron, Ralf
    Binder, Andreas
    Wasner, Gunnar
    [J]. LANCET NEUROLOGY, 2010, 9 (08) : 807 - 819
  • [6] Brook RH., 1979, Conceptualization and measurement of health for adults in the health insurance study: Vol. VIII
  • [7] Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain
    Bruera, E
    Belzile, M
    Pituskin, E
    Fainsinger, R
    Darke, A
    Harsanyi, Z
    Babul, N
    Ford, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3222 - 3229
  • [8] Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study
    Bruera, E
    Palmer, JL
    Bosnjak, S
    Rico, MA
    Moyano, J
    Sweeney, C
    Strasser, F
    Willey, J
    Bertolino, M
    Mathias, C
    Spruyt, O
    Fisch, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 185 - 192
  • [9] Gabapentin for neuropathic cancer pain: A randomized controlled trial from the gabapentin cancer pain study group
    Caraceni, A
    Zecca, E
    Bonezzi, C
    Arcuri, E
    Tur, RY
    Maltoni, M
    Visentin, M
    Gorni, G
    Martini, C
    Tirelli, W
    Barbieri, M
    De Conno, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 2909 - 2917
  • [10] Diagnosis and treatment of neuropathic pain
    Chong, MS
    Bajwa, ZH
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2003, 25 (05) : S4 - S11